E-ISSN 2149-2530
Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer
1 Department of Medical Oncology, Kanuni Training and Research Hospital, Trabzon, Turkey  
2 Department of Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey  
turkthoracj 2017; 18: 101-107
DOI: 10.5152/TurkThoracJ.2017.17006
This article was viewed 322 times, downloaded 151 times

Key Words: Non-small cell lung cancer, immunotherapy, checkpoint inhibitors

More than half of non-small cell lung cancer (NSCLC) patients are at an advanced stage at the time of diagnosis, and they have a poor prognosis. Systemic treatment is the basic treatment approach for advanced-stage NSCLC, and chemotherapy and targeted treatments are commonly used based on the molecular characteristics. Although targeted therapies have led to a significant level of improvement in terms of survival, the results are still unsatisfactory. However, considerable attention has been focused to the immunotherapy with recent positive results reported by studies on this field. In this context, a certain portion of clinical studies have shown dramatic results, and these have involved inhibitors developed particularly against the immune checkpoint protein programmed death receptor-1 and its ligand (programmed death ligand-1). This review aims to present the significance of immune checkpoint inhibitors in NSCLC and to summarize the findings of relevant contemporary clinical studies.


Cite this article as: Kazaz SN, Öztop İ. Immune checkpoint inhibitors in advanced-stage non-small cell lung cancer. Turk Thorac J 2017;18:101-7.

Key Words
Author's Corner
AVES | Copyright © 2018 Turkish Thoracic Society Latest Update: 12.01.2018